Search Results for "Benzodiazepine Multiple Sclerosis"

03:11 EST 8th February 2016 | BioPortfolio

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Amyotrophic lateral sclerosis ALS

Diffuse mesangial sclerosis

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

[Articles] Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

The anti-inflammatory effects of fingolimod did not slow disease progression in primary progressive multiple sclerosis. Therapeutic strategies for primary progressive multiple sclerosis might need dif...

Consortium of Multiple Sclerosis Centers Publishes Rehab Primer

HACKENSACK, NJ -- The Consortium of Multiple Sclerosis Centers (CMSC), in collaboration with The France Foundation (TFF) and Nurse Practitioner Alternatives (NPA), has produced a Rehabilitation Primer...

[Comment] Primary progressive multiple sclerosis—why we are failing

In The Lancet, Fred Lublin and colleagues1 report negative results of a randomised, double-blind trial (INFORMS) assessing the efficacy of fingolimod, an oral sphingosine 1-phosphate receptor (S1PR) m...

Exploring new paths for the treatment of multiple sclerosis

(Edmonton) Research from the University of Alberta's Faculty of Medicine & Dentistry is trailblazing a potential new pathway for the treatment of multiple sclerosis (MS). The research, published in th...

Genentech has positive results for patients with multiple sclerosis

Genentech’s phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) show positive results

Specific subset of b-cell responsible for Multiple Sclerosis disease activity identified.

An estimated 100,000 Canadians live with multiple sclerosis; there is currently no cure for the disease.  Modern scientific understanding has considered multiple sclerosis (MS) to be a disease contr...

[Review] The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets

Identification of the target antigens of pathogenic antibodies and T cells is of fundamental importance for understanding the pathogenesis of multiple sclerosis, and for the development of personalise...

Novartis Buys Rights to Multiple Sclerosis Drug from GlaxoSmithKline

Novartis is acquiring all the remaining rights to GlaxoSmithKline’s (GSK) multiple sclerosis (MS) drug, Ofatumumab. A fully human monoclonal antibody which targets the CD20 molecule, Ofatumumab ...

Matching PubMed Articles

Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.

To date, there are no available factors to predict the outcome after multiple sclerosis relapse.

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.

Data are limited for mortality and comorbidities in patients with multiple sclerosis (MS).

Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis.

Cognitive deficits are common in multiple sclerosis. Most previous studies investigating the imaging substrate of cognitive deficits in multiple sclerosis included patients with relatively short disea...

Season of birth and multiple sclerosis in Tunisia.

Recent studies on date of birth of multiple sclerosis (MS) patients showed an association between month of birth and the risk of developing MS. This association has not been investigated in an African...

Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.

In search of the missing heritability in multiple sclerosis (MS), additional approaches adding to the genetic discoveries of large genome-wide association studies are warranted.

Search Whole site using Google

Quick Search
Advertisement Advertisement